Similar articles

• Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.

  Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T. Hashizume K, et al. N Engl J Med. 1991 Apr 4;324(14):947-53. doi: 10.1056/NEJM199104043241403. N Engl J Med. 1991. PMID: 1900575 Clinical Trial.
• Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.

  He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW. He CT, et al. Clin Endocrinol (Oxf). 2004 Jun;60(6):676-81. doi: 10.1111/j.1365-2265.2004.02032.x. Clin Endocrinol (Oxf). 2004. PMID: 15163329 Clinical Trial.
• Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy.

  Kuo SW, Huang WS, Hu CA, Liao WK, Fung TC, Wu SY. Kuo SW, et al. Eur J Endocrinol. 1994 Aug;131(2):125-30. doi: 10.1530/eje.0.1310125. Eur J Endocrinol. 1994. PMID: 8075781
• Remission of Graves' hyperthyroidism treated with methimazole.

  Bolaños F, González-Ortiz M, Durón H, Sánchez C. Bolaños F, et al. Rev Invest Clin. 2002 Jul-Aug;54(4):307-10. Rev Invest Clin. 2002. PMID: 12415954 Review.
• Recent advances in laboratory tests for autoantibodies to thyrotropin receptor protein in Graves' disease.

  Gupta MK. Gupta MK. Clin Lab Med. 1988 Jun;8(2):303-23. Clin Lab Med. 1988. PMID: 3284698 Review.